RMDNYSESurgical & Medical Instruments & ApparatusFiscal year ends June 30Also trades as RSMDF
RESMED INC
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Aug 13, 2026
$239.77+0.80 (+0.33%)
Close on Oct 19, 2026
- Market cap
- $34.79B
- P/E (TTM)
- 23.0
- Dividend yield
- 1.00%
RESMED INC revenue by segment
By business segment
| Revenue | TTM Q4 26 | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sleep and Breathing Health | $4.98B | $4.87B | $4.74B | $4.61B | $4.50B | $4.40B | $4.31B | $4.21B | $4.10B | – | – | – | 88.0% | +10.5% |
| Residential Care Software | $675.81M | $670.90M | $661.18M | $650.80M | $641.44M | $626.37M | $613.16M | $601.61M | $584.13M | – | – | – | 12.0% | +5.4% |
| Sleep and Respiratory Care | – | – | – | – | – | – | – | – | $4.10B | $4.01B | $3.94B | $3.84B | – | – |
| Operating income | TTM Q4 26 | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sleep and Breathing Health | $2.20B | $2.20B | $2.12B | $2.03B | $1.96B | $1.89B | $1.85B | $1.77B | $1.68B | – | – | – | +12.2% |
| Residential Care Software | $217.73M | $217.63M | $212.56M | $211.40M | $205.00M | $192.29M | $177.86M | $170.77M | $154.45M | – | – | – | +6.2% |
| Sleep and Respiratory Care | – | – | – | – | – | – | – | – | $1.68B | $1.64B | $1.57B | $1.51B | – |
By product or service
| Revenue | TTM Q4 26 | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sleep and Breathing Health | $4.98B | $4.87B | $4.74B | $4.61B | $4.50B | $4.40B | $4.31B | $4.21B | $4.10B | – | – | – | 88.0% | +10.5% |
| Residential Care Software | $675.81M | $670.90M | $661.18M | $650.80M | $641.44M | $626.37M | $613.16M | $601.61M | $584.13M | – | – | – | 12.0% | +5.4% |
| Sleep and Respiratory Care | – | – | – | – | – | – | – | – | $4.10B | $4.01B | $3.94B | $3.84B | – | – |
By region
From the segment and revenue-disaggregation notes of Resmed's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.